Indications |
Oral Severe chronic spasticity Adult: Initially, 5 mg tid for 3 days increased to 10 mg tid for 3 days, then in similar increments and intervals until either 20 mg tid is reached or until desired effect is obtained. Max: 100 mg daily. Child: 0.75-2 mg/kg daily. May initiate with 2.5 mg 4 times daily, increased gradually every 3 days until desired effect is obtained. Maintenance: 6-10 yr: 30-60 mg daily; 2-6 yr: 20-30 mg daily; 12 mth-2 yr: 10-20 mg daily. Max: >10 yr: 2.5 mg/kg daily. Elderly: Initiate with lower doses. Renal impairment: Dose reduction may be required. Patients on chronic haemodialysis: 5 mg daily. Intrathecal Severe chronic spasticity Adult: Test dose: 25 or 50 mcg administered into the intrathecal space by barbotage over at least 1 minute; increase dose by 25 mcg not more often than every 24 hr until 100 mcg/dose to determine appropriate dose. Non-responders to a test dose of 100 mcg are not suitable for intrathecal treatment. For responders with response lasting >8-12 hr, the test dose that was used to produce the response can be given as a 24-hr infusion; if the test-dose response lasted ≤8-12 hr, then a dose equivalent to twice the test dose is given. Adjust daily dosage as required. Maintenance: 12 mcg-2 mg daily for spasticity of spinal origin; 22 mcg-1.4 mg daily for spasticity of cerebral origin. Child: 4-18 yr with spasticity of cerebral origin: Initially, 25 mcg over at least 1 minute via catheter or lumbar puncture, increase by 25 mcg every 24 hr to a max of 100 mcg to determine appropriate dose then dose-titration phase. Maintenance: <12 yr: 24 mcg-1.2 mg daily; >12 yr: 1.4 mg daily. |
Contraindications |
Hypersensitivity. Active peptic ulcer disease. |
Warnings / Precautions |
Cerebrovascular disorders, epilepsy, severe psychotic disorders, confusional states, history of peptic ulcer, resp depression, diabetes (DM), hepatic or renal impairment, elderly, pregnancy. Avoid sudden withdrawal. |
Adverse Reactions |
Sedation, drowsiness, ataxia, dizziness, headache, confusion, hallucinations, skin reactions, GI symptoms, enuresis. Potentially Fatal: Respiratory or CV depression, seizures. |
Overdose Reactions |
Symptoms include muscular hypotonia, drowsiness, respiratory depression, coma and convulsions. Gastric lavage may be used. |
Drug Interactions |
Hypotensive effect may be increased with antihypertensives. Concomittant use with levodopa in Parkinson patients may result in confusion, agitation, hallucinations. Potentially Fatal: CNS depressants and alcohol may potentiate CNS effects. See Below for More baclofen Drug Interactions |
Mechanism of Actions |
Baclofen is an antispastic. It inhibits both monosynaptic and polysynaptic reflexes at spinal level. Absorption: Rapidly and almost completely absorbed from GIT (oral); peak plasma conc after 1-3 hr. Distribution: Blood-brain barrier, CSF (equivalent to 12% conc found in plasma). Protein-binding: 30%. Metabolism: Hepatic (15% of the dose). Excretion: Via urine (70-80% as unchanged drug); elimination half-life (Via urine (70-80% as unchanged drug); elimination half-life (t1/2): 3-4 hr (plasma), 5 hr (CSF). 3-4 hr (plasma), 5 hr (CSF). |
Administration |
Should be taken with food. |
Storage Conditions |
Oral: Store below 25°C. |
ATC Classification |
M03BX01 - baclofen ; Belongs to the class of other centrally-acting muscle relaxants. |
Storage |
Oral: Store below 25°C. |
Available As |
|
Baclofen
Post Review about Baclofen Click here to cancel reply.
Baclofen Containing Brands
Baclofen is used in following diseases
Drug - Drug Interactions of Baclofen
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.